HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project
|
|
- Chad Williams
- 5 years ago
- Views:
Transcription
1 DOI: /hiv ORIGINAL RESEARCH HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project NS Ku, 1 Y Lee, 2 JY Ahn, 1 JE Song, 1 MH Kim, 1 SB Kim, 1 SJ Jeong, 1 K-W Hong, 3 E Kim, 2 SH Han, 1 JY Song, 3 HJ Cheong, 3 YG Song, 1 WJ Kim, 3 JM Kim, 1 DM Smith 4,5 and JY Choi 1 1 Department of Internal Medicine and AIDS Research Institute, Seoul, South Korea, 2 Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, South Korea, 3 Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea, 4 Department of Medicine, University of California San Diego, La Jolla, CA, USA and 5 Veterans Affairs San Diego Healthcare System, San Diego, CA, USA Objectives HIV-associated neurocognitive disorder (HAND) is an independent predictor of early mortality and is associated with many difficulties in activities of daily living. We sought to determine the prevalence of and risk factors for HAND in HIV-infected Koreans. In addition, we investigated the performance of screening tools and components of neuropsychological (NP) tests for diagnosing HAND. Methods HIV-infected patients were enrolled consecutively from two different urban teaching hospitals in Seoul, South Korea between March 2012 and September Participants completed a detailed NP assessment of six cognitive domains commonly affected by HIV. The Frascati criteria were used for diagnosing HAND. Four key questions, the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment (MoCA)-K were also assessed as potential tools for screening for HAND. Results Among the 194 participants, the prevalence of HAND was 26.3%. Asymptomatic neurocognitive impairment and minor neurocognitive disorder accounted for 52.9 and 47.1% of the patients with HAND, respectively. In multivariate analysis, haemoglobin (Hb) level 13 g/dl (P = 0.046) and current use of a protease inhibitor-based regimen (P = 0.031) were independent risk factors for HAND. The sensitivity and specificity of the IHDS were 72.6 and 60.8%, and those of MoCA-K were 52.9 and 73.4%, respectively. The IHDS (P < 0.001) and MoCA-K (P < 0.001) were both useful for screening for HAND. Among NP tests, the sensitivity and specificity of the Grooved Pegboard Test were 90.2 and 72.0%, and those of the Wisconsin Card Sorting Test were 61.2 and 84.4%, respectively. Conclusions HAND is a prevalent comorbidity in HIV-infected Koreans. Active screening and diagnosis with effective tools, such as the IHDS, MoCA-K and Grooved Pegboard Test, could be used to identify this important complication. Keywords: HIV, HIV-associated neurocognitive disorder (HAND), neuropsychological tests, risk factors, screening tool Accepted 9 January 2014 Introduction Correspondence: Dr Jun Yong Choi, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul , Republic of Korea. Tel: ; fax: ; seran@yuhs.ac HIV may enter the central nervous system (CNS) early after infection [1] and, although it does not directly infect neurons, it is frequently associated with structural and functional brain abnormalities [2 5]. This CNS infection can 470
2 HAND in HIV-infected Koreans 471 lead to neurocognitive impairment. This HIV-associated neurocognitive disorder (HAND) strongly predicts a wide variety of difficulties in activities of daily living, such as employment, automobile driving, medication adherence, financial management, shopping, cooking and use of public transportation [6]. Moreover, viral levels in the cerebrospinal fluid (CSF) have been associated with HAND in HIVunsuppressed patients with AIDS [7], while suppression of CSF HIV can be associated with improvement in cognition [8]. However, in the era of combination antiretroviral therapy (cart), HAND in Western countries is still common (being found in 16 52% of HIV-infected individuals), even when cart is successful with suppression of viral load [9 14]. The extent to which cart leads to a reduction in the incidence and prevalence of HIV-related cognitive impairment remains unclear. Additionally, most neurocognitive research in HIV-infected individuals has been conducted in Western populations, and the burden of HAND in Korean HIV-infected individuals is so far unknown. Furthermore, there are few studies that have investigated how to screen HIV-infected individuals for HAND and the diagnostic validation of neuropsychological (NP) tests for diagnosing HAND among HIV-infected Asian persons. Methods Study design Two hundred HIV-infected patients who were 18 years old or older were recruited consecutively in Severance Hospital and Korea University Guro Hospital between March 2012 and September 2012 in Seoul, Korea. All subjects provided informed consent and received standardized neurological, NP and functional assessments at two study sites. This study was approved by the Institutional Review Board of the hospital (IRB # ). The exclusion criteria were (1) recent and/or significant traumatic brain injury; (2) a neurological disorder not related to HIV infection; (3) infections that can affect the CNS; (4) a significant CNS opportunistic infection based upon history and/or neuromedical examination; (5) a current or past psychotic disorder; (6) significant substance use (more than three alcoholic drinks per day over the last month or recreational drug use more than once per week during the last month); (7) symptoms of a current, active infection, a body temperature of > 38.5 C at the time of recruitment or current treatment for a serious, systemic infection within 3 months; (8) colour blindness; (9) a hearing deficit that appears to affect auditory comprehension [15]. Six of the two hundred subjects were excluded because of confounding comorbidity (five subjects) or because they withdrew early from the study (one subject). Enrolled participants underwent demographic, clinical and NP assessments. At baseline visits, a neuromedical history was obtained and a standardized examination, neurobehavioural testing, and structured evaluation of selected psychiatric variables were performed. The following variables were also assessed: age at first visit, gender, body mass index (BMI), haemoglobin (Hb) level, level of education, duration of HIV infection, Centers for Disease Control and Prevention (CDC) classification, reported mode of transmission, prior AIDS diagnosis, hepatitis B or C virus coinfection, antiretroviral therapy regimen [two nucleoside reverse transcriptase inhibitors (NRTIs) plus a nonnucleoside reverse transcriptase inhibitor (NNRTI), two NRTIs plus a protease inhibitor (PI), or another combination], CNS penetration effectiveness (CPE) score [16], initial CD4 T-cell count, pre-cart CD4 T-cell count, current CD4 T-cell count, lowest CD4 T-cell count, initial viral load (VL), pre-cart VL, current VL, and highest VL. Additionally, a clinician administered the depression questionnaire [17] and interview for assessing depression and substance use history. The Karnofsky Performance Status Scale [18] was used to assess functional impairments. Also, eight questions in Korean designed by the authors based on the suggestions of Antinori et al. [15] were used to assess functional activities; these translate as: Is it hard to take medication in the correct dosages at the correct time? ; Is it hard to manage financial matters independently (budgeting, writing cheques, paying rent and bills, going to the bank)? ; Is it hard to perform household tasks alone or with occasional assistance? ; Do you have trouble managing your daily schedule? ; Do you make more mistakes in your working? ; Do you need more time than before to do the same amount of work? ; Do you find it more difficult than before to carry out tasks successfully? ; Are you less able to produce your best work?. Neuromedical evaluation Neuromedical assessments were standardized between study sites and included multiple, linked evaluations. These evaluations included the following elements. (1) Medical history. Standardized forms were used to record medical and neurological symptoms. Medical conditions were classified using International Classification of Diseases 9th Revision, Clinical Modification (ICD-9-CM) codes, and HIV disease stage was classified according to 1993 CDC guidelines [19]. Staff also administered a brief questionnaire to collect information about HIV risk behaviour. (2) Current medications, medication history, and adherence. A clinician recorded prescribed medications taken
3 472 NS Ku et al. for longer than 1 month. Detailed information about past and present ART use was obtained. Each site used the Adherence Scale to Anti-HIV Medications form to collect ART adherence data [20]. (3) Neurological and general physical examinations. The research clinician performed a standardized neurological, medical examination that included assessment of vital signs, height and weight, mental status, cranial nerves, motor, sensory and cerebellar function, reflexes and gait. The medical staff also performed a general physical examination and noted health-related functioning. Assessment of the screening tool Four key questions proposed by the Asia, Australia, Africa and Middle East (AAAME) HAND Advisory Board as a screening tool (unpublished data) to evaluate early potential signs of neurocognitive impairment and depression were put to participants: Are you slower in your thinking processes? ; Are you more forgetful? ; Is it harder to organize things? and Are you less able to find pleasure in things you used to enjoy? Also, the International HIV Dementia Scale (IHDS) [21] and Montreal Cognitive Assessment (MoCA)-K [22] were evaluated as screening tools for diagnosing HAND. The most useful cut-off values for each screening test were also investigated. Neuropsychological tests In order to establish rates of HAND, we used NP test norms based on results for HIV-negative subjects[23 27]. The neurobehavioural evaluation assessed six ability domains (Supplementary Table S1). These are well-established measures that have been used in numerous studies of HIV/AIDS. In addition to providing individual NP test results, the battery facilitates clinical determination of the level of impairment within each domain, as well as the global level of impairment based on population-specific normative standards. This approach has shown good interrater reliability, even across raters at different institutions [28]. Diagnosis of HAND Subjects completed a detailed NP assessment measuring their functioning in six cognitive domains known to be commonly affected by HIV infection. The Frascati criteria were used to diagnose HAND, which was classified as asymptomatic neurocognitive impairment (ANI), minor neurocognitive disorder (MND) and HIV-associated dementia (HAD) [15]. Statistical analyses An independent t-test or χ 2 test was used to assess differences in each variable between neurocognitively impaired and nonimpaired subjects. To identify independent factors associated with HAND, a multivariate logistic regression analysis was performed which included the variables that were significantly associated with HAND in the univariate analysis (P < 0.05) and well-known as a risk factor of HAND. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were then calculated in comparison with the reference diagnosis, which was based on cases of HAND. In addition, we conducted a receiver operating characteristic (ROC) curve analysis to compare the predictive accuracies of screening tools and the area under the curve (AUC) was calculated. The 95% confidence interval (CI) was calculated using the Wilson score method. All P-values are two-tailed and P < 0.05 was considered statistically significant. All analyses were performed using SPSS for Windows 12.0 (SPSS, Chicago, IL). Results General characteristics of study subjects Of the 194 enrolled subjects, 93.8% were male, and the mean age (range) was (21 72) years. The most common exposure category was men who have sex with men (MSM) (52.6%), followed by heterosexual contact (27.3%). The mean [± standard deviation (SD)] duration of education was 13.4 ± 3.3 years, and 31.9 and 27.9% of the subjects were at clinical CDC stages B and C of HIV disease, respectively. The mean (± SD) current CD4 T-cell count was ± cells/μl and the mean (± SD) current viral load was 2.0 ± 1.4 log 10 HIV-1 RNA copies/ml (Table 1). Prevalence and clinical characteristics of HAND The overall prevalence of HAND in the study cohort was 26.3%. Of the 51 participants with HAND, 52.9 and 47.1%, respectively, had ANI and MND. No individuals were diagnosed with HAD. Of those with HAND, the mean age (range) was (21 70) years, and 96.1% of them were male. The most common exposure category was MSM (47.1%), followed by heterosexual contact (33.3%). The mean (± SD) duration of education was 12.8 ± 3.4 years. The mean (± SD) Hb level was 13.6 ± 1.8 g/dl, with 15% having Hb < 13.0 g/dl. Initial and current mean (± SD) CD4 T-cell counts were ± and ± cells/ μl, respectively. Initial and current mean (± SD) viral loads were 4.7 ± 1.3 and 2.4 ± 1.7 log 10 copies/ml, respectively, and 71.7% of subjects were on a cart regimen of two NRTIs plus a PI (Table 1). Also, 82% of study participants
4 HAND in HIV-infected Koreans 473 Table 1 Baseline characteristics and factors associated with HIV-associated neurocognitive disorder (HAND) in HIV-infected individuals Variable Total (n = 194) Patients with HAND (n =51) Patients without HAND (n = 143) P-value Multivariate analysis Odds ratio (95% CI) P-value Age (years) [mean (range)] (21 72) (21 70) (25 72) Male gender [n (%)] 182 (93.8) 49 (96.1) 133 (93.0) BMI (kg/m 2 ) (mean ± SD) 23.0 ± ± ± Haemoglobin 13.0 g/dl [n (%)] 15 (29.4) 22 (15.4) ( ) Education (years) (mean ± SD) 13.4 ± ± ± Mode of transmission [n (%)] Homosexual contact 102 (52.6) 24 (47.1) 78 (54.5) Heterosexual contact 53 (27.3) 17 (33.3) 36 (25.2) Unknown and others 39 (20.1) 10 (19.6) 29 (20.3) Duration of HIV infection (years) (mean ± SD) 77.7 ± ± ± Previous AIDS diagnosis [n (%)] 55 (28.4) 18 (35.3) 37 (25.9) AIDS at diagnosis [n (%)] No (33.3) 59 (41.3) Yes (66.7) 84 (58.7) Initial CD4 count (cells/μl) (mean ± SD) ± ± ± Initial VL (log 10 copies/ml) (mean ± SD) 4.8 ± ± ± Pre-cART CD4 count (cells/μl) (mean ± SD) ± ± ± Pre-cART VL (log 10 copies/ml) (mean ± SD) 5.0 ± ± ± Current CD4 count (cells/μl) (mean ± SD) ± ± ± ( ) Current VL (log 10 copies/ml) (mean ± SD) 2.0 ± ± ± Nadir CD4 count (cells/μl) (mean ± SD) ± ± ± Highest VL (log 10 copies/ml) (mean ± SD) 5.0 ± ± ± Current cart [n (%)] No treatment 20 (10.3) 7 (13.7) 13 (9.1) NRTIs + PI 104 (59.8) 32 (72.7) 72 (55.4) ( ) NRTIs + NNRTI 49 (28.2) 7 (15.9) 42 (32.3) NRTIs + II 12 (6.9) 3 (6.8) 9 (6.9) NRTIs 3 (1.7) 0 (0.0) 3 (2.3) Other 6 (3.4) 2 (4.5) 4 (3.1) CPE rank (mean ± SD) 6.7 ± ± HCV coinfection [n (%)] 6 (3.7) 3 (6.7) 3 (2.6) HBV coinfection [n (%)] 9 (5.3) 2 (4.3) 7 (5.6) BMI, body mass index; cart, combination antiretroviral therapy; CI, confidence interval; IQR, interquartile range; VL, viral load; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; II, integrase inhibitor; CPE, central nervous system penetration effectiveness; HCV, hepatitis C virus; HBV, hepatitis B virus; SD, standard deviation. with HAND receiving cart in our cohort had suppressed viral loads (< 50 copies/ml). In the individuals with HAND, among the six cognitive functioning domains, impairment of sensory perceptual/motor skills was the most common (90.2%), followed by abstraction/executive impairment (78.0%) and memory (learning and recall) impairment (48.0%) (Table 2). In univariate analysis, Hb levels 13 g/dl (P = 0.029) and current use of a PI-based regimen (P = 0.043) were the only factors significantly associated with HAND. The significance remained for both Hb level (P = 0.046) and current use of a PI-based regimen in multivariate analysis (P = 0.031) (Table 1). The performance of screening tests for HAND The sensitivity and specificity of the IHDS were 72.6 and 60.8%, and those of MoCA-K were 52.9 and 73.4%, respectively (Table 3). The MoCA-K and IHDS screening test Table 2 Impairment in six domains of cognitive functioning in 51 Korean HIV-infected individuals with HIV-associated neurocognitive disorder (HAND) Domain Verbal/language 2 (3.9) Attention/working memory 3 (5.9) Abstraction/executive 39 (78.0) Memory (learning and recall) 24 (48.0) Speed of information processing 1 (2.0) Sensory perceptual/motor skills 46 (90.2) Patients with HAND who showed impairment [n (%)] scores were significantly correlated with HAND, and cutoff values of 25 and 10 were the most useful in diagnosing HAND, respectively (Table 3 and Tables S2 and S3). To compare the predictive accuracies of MoCA-K and the IHDS as screening tools, a ROC analysis was performed (Fig. 1), which demonstrated that the AUCs of the IHDS and
5 474 NS Ku et al. Table 3 Diagnostic performance of the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment (MoCA)-K NP test Sensitivity % (95% CI) Specificity % (95% CI) Accuracy % (95% CI) IHDS ( ) ( ) ( ) MoCA-K ( ) ( ) ( ) p-value for comparison CI, confidence interval; NP, neuropsychological. Discussion Fig. 1 Areas under the curve (AUCs) for the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment (MoCA)-K for diagnosing HIV-associated neurocognitive disorder (HAND). ROC, receiver operating characteristic. MoCA-K for diagnosing HAND were (P < 0.001) and (P < 0.001), respectively. However, the four key questions devised for use as a screening tool did not significantly correlate with the diagnosis of HAND by standard methods (Table S4). NP tests for diagnosing HAND Diagnostic characteristics for each NP test for diagnosing HAND in HIV-infected Koreans are provided in Table 4. Among NP tests, the Grooved Pegboard Test had the highest sensitivity and modest specificity (90.2 and 72.0%, respectively). The next highest scoring NP test was the Wisconsin Card Sorting Test, which had a sensitivity and specificity of 61.2 and 84.4%, respectively. The other NP tests had much lower sensitivity but higher specificity. This is the first study of the prevalence of HAND in HIVinfected patients in Korea. We found that approximately a quarter of our patients had HAND (26.3%). Of these individuals, 52.9% had ANI and 47.1% had MND. Of those with HAND, 82% were receiving cart with suppressed viral loads, suggesting that suppressing HIV replication might be not sufficient to treat HAND. These results are similar to reports from Western countries, with the reported prevalence of HAND being 16 38% in the era of cart [9 13]. Our study also found a lower Hb level and use of a current PI-based cart regimen to be independent risk factors for HAND. Although low Hb levels may represent underlying chronic disease, the specific mechanism of the effect of low Hb on the occurrence of HAND is unclear, although previous studies have also noted a low Hb level as a risk factor for HAND [29] and HAD [30]. The reason for the observed significant correlation between the current use of a PI-based cart regimen and HAND is unclear, but it may be an effect of the clinician s efforts to treat HAND rather than indicating that use of a PI-based regimen is an independent risk factor for HAND. In other words, we speculate that cart might have been switched to a PI-based regimen because of memory impairment in HIVinfected patients. Such a switch may have been made because NNRTIs such as efavirenz have been reported to be risk factors for HAND [31] and most PIs have high CPE scores [32]. Thus, in our study, HIV-infected patients with HAND seemed to be receiving a PI-based regimen more frequently than those without HAND. Another reason for the association between PIs and HAND may be that clinicians may tend to prescribe PI-based cart regimens rather than NNRTI-based regimens for patients who are more ill. Some studies of Western cohorts have reported that low nadir CD4 T-cell counts were an independent risk factor for HAND [33 35], but this was not observed in our cohort. In our study, the interquartile range of nadir CD4 T-cell counts of all participants was cells/μl and, in particular, the 25% quartile was higher than that of Ellis et al. [33]. This may be because there was a tendency to start cart earlier in Korea; thus, we speculate that nadir CD4 T-cell count was not significantly associated with
6 HAND in HIV-infected Koreans 475 Table 4 Diagnostic value of neuropsychological tests for diagnosing HIV-associated neurocognitive disorder (HAND) in Korean HIV-infected individuals Cognitive domain and neuropsychological test Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) Accuracy % (95% CI) Speed of information processing K-WAIS Digit Symbol Subtest 1.96 ( ) ( ) ( ) ( ) ( ) Trail Making Test, Part A 0.00 ( ) ( ) ( ) ( ) Memory (learning and recall) K-Auditory Verbal Learning Test (K-AVLT) 6.00 ( ) ( ) ( ) ( ) ( ) K-Complex Figure Test (K-CFT) 9.80 ( ) ( ) ( ) ( ) ( ) Abstraction/executive Wisconsin Card Sorting Test (128-item) ( ) ( ) ( ) ( ) ( ) K-WAIS Similarity Subtest 4.00 ( ) ( ) ( ) ( ) ( ) Trail Making Test, Part B ( ) ( ) ( ) ( ) ( ) Attention/working memory K-WAIS Digit Span Subtest 5.88 ( ) ( ) ( ) ( ) ( ) Sensory perceptual/motor skills Grooved Pegboard Test (Dominant and ( ) ( ) ( ) ( ) ( ) Non-dominant Test) Verbal/language K-WAIS Vocabulary Subtest 3.92 ( ) ( ) ( ) ( ) ( ) CI, confidence interval; K-WAIS, K-Wechsler Adult Intelligence Scale; NPV, negative predictive value; PPV, positive predictive value. HAND because of the overall higher CD4 counts in our population. As the prevalence of HAND in our population was similar to that in the Western reports, this finding may suggest that nadir CD4 count may in fact be a confounder with and not a predictor of HAND. In our study, the IHDS and MoCA-K measures used as screening tools for HAND showed better performance than the four key questions. As the IHDS is widely used as a screening tool for HAD [21], it has the potential to be a useful screening instrument for HAND. In our study, participants who were classified as having neurocognitive impairment on the IHDS also performed significantly less well on other tests of cognitive function, especially those of processing speed and verbal learning/memory [36]. MoCA is a brief cognitive screening tool with high sensitivity and specificity for detecting mild cognitive impairment or dementia [22,37], and in our study, a cutoff value of 26 (scores of 25 indicate impairment) yielded the best balance between sensitivity and specificity for HAND. As clinicians often depend on patients to self-report memory complaints, especially in the early stages of cognitive impairment, we attempted to develop a screening tool with four questions, but this tool was not found to be reliable. We speculate that this may have been because patients might not have answered the questions frankly. Beyond screening tools, we also investigated which NP tests had the best sensitivity and specificity for diagnosing HAND. We found that the Grooved Pegboard Test and Wisconsin Card Sorting Test had the best sensitivity and specificity in our study population. In particular, the Grooved Pegboard Test is a commonly used measure of psychomotor slowing in HIV-positive populations [38], and it has been reported that it can significantly differentiate HIV-infected patients with and without dementia [39]. Therefore, the Grooved Pegboard Test may be useful in diagnosing HAND in HIV-infected Koreans. Our study had some limitations. First, although there were 194 well-characterized participants in the study, the sample size of those with HAND was only 51. The small sample size has the possibility to influence results due to an unequal distribution of impairment. Secondly, there were no patients with HAD in this study. This may represent a selection bias, i.e. those with HAD may not have been able to consent to participate in the study. Thirdly, our results are not applicable to women with HIV infection because 93.8% of the enrolled patients were men; however, the study sample was representative of the Korean HIVinfected population [40]. Fourthly, the study was conducted in Korean among HIV-infected patients in an urban outpatient clinic, which may not be representative of HIVinfected individuals in a community or rural setting or of the general Korean HIV-infected population. Lastly, the possibility of the presence of peripheral neuropathy in patients with HAND influencing NP tests, especially the Grooved Pegboard Test, was not excluded by neurological examination. In conclusion, HAND is a prevalent comorbidity among HIV-infected Koreans. Active screening and diagnosis with effective tools such as the IHDS, MoCA-K and Grooved Pegboard Test should probably be performed in order not to overlook this important complication.
7 476 NS Ku et al. Acknowledgements This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2013R1A1A and NRF E00015), a Chronic Infectious Disease Cohort grant ( ) from the Korea Centers for Disease Control and Prevention, and a grant from the Korean Society for AIDS. This research was also supported by the US National Institutes of Health (NIH) (grants AI100665, AI36214, MH097520, MH83552 and MH62512). Statistical advice was provided by the statistician Hye Sun Lee, M.S., at the Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea. Conflicts of interest: The authors have no conflicts of interest to declare. References 1 Sonnerborg AB, Ehrnst AC, Bergdahl SK, Pehrson PO, Skoldenberg BR, Strannegard OO. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988; 2: Chang L. In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Rev Neurosci 1995; 6: Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999; 52: Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992; 32: Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 1992; 66: Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: Ellis RJ, Hsia K, Spector SA et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: Letendre SL, McCutchan JA, Childers ME et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56: Fernandes Filho SM, de Melo HR. Frequency and risk factors for HIV-associated neurocognitive disorder and depression in older individuals with HIV in northeastern Brazil. Int Psychogeriatr 2012; 24: Robertson KR, Smurzynski M, Parsons TD et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: Cysique LA, Brew BJ. Prevalence of non-confounded HIVassociated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17: Simioni S, Cavassini M, Annoni JM et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1: Heaton RK, Clifford DB, Franklin DR, Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: Smurzynski M, Wu K, Letendre S et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53: revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: Amico KR, Fisher WA, Cornman DH et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42: Sacktor NC, Wong M, Nakasujja N et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19: Lee JY, Dong Woo L, Cho SJ et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008; 21: Yeom TH, Park YS, Oh KJ, Lee YH. Korean Version Wechsler Adult Intelligence Scale. Seoul, Korea Guidance, Kim M, Hyun MH. Relationships between Trail Making Test (A, B, B-A, B/A) scores and age, education, comparison of performance head injury patient and psychiatric patient, The Korean. J Clin Psychol 2004; 23:
8 HAND in HIV-infected Koreans Kim HK. Rey-Kim Memory Test. Seoul, Publishing Neuropsychology, Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual, Revised and Expanded. Odessa, FL, Psychological Assessment Resources, Inc., Lee TY. Normative values for the Grooved Pegboard Test in Adult. Phys Ther Kor 2001; 8: Woods SP, Rippeth JD, Frol AB et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26: Njamnshi AK, Bissek AC, Ongolo-Zogo P et al. Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-saharan Africa: the case of Yaounde-Cameroon. J Neurol Sci 2009; 285: McArthur JC, Hoover DR, Bacellar H et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43: Ciccarelli N, Fabbiani M, Di Giambenedetto S et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: Ellis RJ, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25: Valcour V, Yee P, Williams AE et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection The Hawaii Aging with HIV Cohort. J Neurovirol 2006; 12: McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med 2013; 14: Lawler K, Mosepele M, Ratcliffe S et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 2010; 13: Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: Bryden PJ, Roy EA. A new method of administering the Grooved Pegboard Test: performance as a function of handedness and sex. Brain Cogn 2005; 58: Davis HF, Skolasky RL, Jr, Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12: 29 31, Korea Centers of Disease Control and Prevention Annual Report on the Notified HIV/AIDS in Korea. PHWR 2012; 5: Supporting information Additional Supporting Information may be found in the online version of this article at the publisher s web-site: Table S1. Six cognitive domains and neuropsychological tests. Table S2. The usefulness of IHDS for diagnosing HAND in Korean HIV-infected individuals. Table S3. The usefulness of MoCA-K for diagnosing HAND in Korean HIV-infected individuals. Table S4. The usefulness of four key questions for diagnosing HAND in Korean HIV-infected individuals.
International Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationGood Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection
BRIEF REPORT: CLINICAL SCIENCE Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection Gustavo D. Lopardo, MD,* Emiliano Bissio, MD,* María del C. Iannella,*
More informationApproach to HIV Associated Neurocognitive disorders (HAND)
Approach to HIV Associated Neurocognitive disorders (HAND) Dinesh Singh MB ChB (Natal), M Med (Psych) (Natal), F CPsych (SA), MS (epi) (Columbia, USA), PhD (candidate UKZN) 2 October 2009 ICC, Durban Overview
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationCOGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL Principal Investigator Dr. Zaheer Bagha Supervisors Prof. E. Amayo Prof. A. M. Adam Dr. J. O. Mecha INTRODUCTION
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationHIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
More informationMeasurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History Group Means for NP and MMPI Variables N=381 Consecutive
More informationThe prevalence of HIV-associated neurocognitive
The authors investigated the combined age and HIV effects on cognitive functions in 146 individuals, 116 of whom had HIV infection. Fortytwo percent had HIV-associated neurocognitive disorder, and all
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHAND is Common and Important in Patients on ART
HAND is Common and Important in Patients on ART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego How is HAND diagnosed? How prevalent is it? Points
More informationIssues of Neuropsychological Assessment in International Settings
Issues of Neuropsychological Assessment in International Settings Kevin Robertson, Ph.D. Director of Neuropsychology, Neurology University of North Carolina at Chapel Hill Igor Grant, M.D. Director, HIV
More informationHow to Implement this Assessment in the Clinical Prac5ce?
5th Interna*onal Symposium on Neuropsychiatry HIV - - - Barcelona, May 24-25th, 2012 Neuropsychological Screening in HIV Infec6on: How to Implement this Assessment in the Clinical Prac5ce? Jose A. Muñoz-
More informationCognitive impairment among Indonesia HIV naïve patients
Neurology Asia 2015; 20(2) : 155 160 Cognitive impairment among Indonesia HIV naïve patients 1 Riwanti Estiasari MD, 1 Darma Imran MD, 1 Diatri Nari Lastri MD, 1 Pukovisa Prawirohardjo MD, 1,2 Patricia
More informationAntiviral Therapy 2015; 20: (doi: /IMP2926)
Antiviral Therapy 2015; 20:441 447 (doi: 10.3851/IMP2926) Original article Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for
More informationHigh rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
More informationForget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant
More informationImprovement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors
(2000) 6, 84 ± 88 ã 2000, Inc. www.jneurovirol.com Short Communication Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors Ned Charlton Sacktor*,1, Richard
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationORIGINAL CONTRIBUTION. Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion
ORIGINAL CONTRIBUTION Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion Thomas D. Marcotte, PhD; Reena Deutsch, PhD; J. Allen McCutchan, MD;
More informationDetecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors? Jennifer Lewis, PsyD; Mathew Hirsch, PsyD & Susan Abramowitz, PhD NYU School of Medicine, New York, NY Friday,
More informationHIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP
HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP Educational Objectives By the end of the session, learners will be able to: 1. Describe
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea Supplemental Methods Participants From
More informationOriginal Article. J Young Pharm, 2016; 8(3): A multifaceted peer reviewed journal in the field of Pharmacy
J Young Pharm, 2016; 8(3): 279-283 A multifaceted peer reviewed journal in the field of Pharmacy www.jyoungpharm.org www.phcog.net Original Article Impact of HIV associated neurocognitive disorders on
More informationDifferential diagnosis between depression and neurocognitive impairment in HIV-infected persons
Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto - Canada Disclosure Research: Canadian Institute
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS
HIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS Hans-Jürgen von Giesen, M.D. Bernhard A. Haslinger, M.D. Simone Rohe Hubertus Köller, M.D. Gabriele Arendt, M.D.
More informationInternational HIV Dementia Scale:
ORIGINAL RESEARCH International HIV Dementia Scale: screening for HIV-associated neurocognitive disorders in occupational settings CH Van Wijk 1,2 and WAJ Meintjes 2 1 Institute for Maritime Medicine,
More informationNeurocognitive impairment still occurs in HIV-infected individuals even in those treated with highly active
REVIEWS IMAJ VOL 17 JANUARY 2015 HIV-Associated Neurocognitive Disorders (HAND) Daniel Elbirt MD 1, Keren Mahlab-Guri MD 1, Shira Bezalel-Rosenberg MD 1, Harpreet Gill BHSc 2, Malka Attali MD 1 and Ilan
More informationDSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City
Diagnosis and Monitoring of HAND Karl Goodkin, MD, PhD Professor and Chair Department of Psychiatry and Behavioral Sciences East Tennessee State University Norman C. Moore, MD Director of Research, Professor
More informationHIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
More informationClassification of Pediatric HIV CNS Disease: Comparison of CNS and Systemic Disease Markers of Children Treated in the HAART Era
Classification of Pediatric HIV CNS Disease: Comparison of CNS and Systemic Disease Markers of Children Treated in the HAART Era Pam Wolters, Staci Martin, Maryanne Tamula, Steven Zeichner, Lucy Civitello,
More informationDefinitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders Prepared by Igor Grant for Working Group 1 consisting of: Desiree Byrd, Mariana Cherner, David
More informationDynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy
Published Ahead of Print on May 27, 2009 as 10.1212/WNL.0b013e3181ab2b3b Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy L.A. Cysique, PhD F. Vaida, PhD
More informationLow prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons Nancy F. Crum-Cianflone, David J. Moore, Scott Letendre, et al. Neurology 2013;80;371; Published online before
More informationAsymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline Igor Grant, MD Donald R. Franklin, Jr., BS Reena Deutsch, PhD Steven P. Woods, PsyD Florin Vaida, PhD Ronald
More informationProgress in understanding the pathogenesis of HIV-1-
The authors previously found a strong association between elevated HIV proviral DNA (HIV DNA) and a diagnosis of HIV-1-associated dementia (HAD) vs. normal cognition. It is unclear whether HIV DNA globally
More informationNeurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions
Neurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions Sean B. Rourke, Ph.D. Scientist and Neuropsychologist, St. Michael s Hospital Director, CIHR
More informationDr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual Conference of the
More informationAIDS 2011, 3, 2011 RW
Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease
More informationNeuropsychological assessment in HIV/AIDS and its challenges in Galati County
Neuropsychological assessment in HIV/AIDS and its challenges in Galati County Manuela Arbune Dunarea de Jos U i e sit Galati București, October 5-6, 2015 Background HAND persists despite ARV (~50%). Neu
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationCOGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS PARIYA L. FAZELI
COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS by PARIYA L. FAZELI DAVID E. VANCE, COMMITTEE CO-CHAIR KARLENE K. BALL, COMMITTEE CO-CHAIR VIRGINIA
More informationMetabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV
Metabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV Jessica L. Montoya, Ph.D. Postdoctoral Fellow Department of Psychiatry, UC San Diego 9 th International Workshop
More informationCan high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? Matteo Vassallo a,b, Jacques Durant a, Virginie Biscay a, Christine
More informationIdentification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort
Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort David J. Moore 1 *, Mollie J. P. Roediger 2,3, Lynn E. Eberly
More informationCAB 59: HIV and neurocogni5ve impairment
HIV Neurology CAB 59: HIV and neurocogni5ve impairment Friday 8 th July 2016 Dr Nick Davies Consultant Neurologist, Chelsea & Westminster Hospital & Imperial College NHS Trust (Charing Cross Hospital),
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationThe prevalence and incidence of neurocognitive impairment in the HAART era
The prevalence and incidence of neurocognitive impairment in the HAART era Kevin R. Robertson a, Marlene Smurzynski b, Thomas D. Parsons a, Kunling Wu b, Ronald J. Bosch b, Julia Wu b, Justin C. McArthur
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationClinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationImpact of Antiretroviral Regimens on CSF Viral Escape in a Prospective Multicohort
Impact of Antiretroviral Regimens on CSF Viral Escape in a Prospective Multicohort Study of ART-Experienced HIV-1 Infected Adults in the United States Authors: Shibani S. Mukerji 1,2 ; Vikas Misra 1 ;
More informationThe Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV LYNN KAKOS, PH.D. VA MARYLAND HEALTH CARE SYSTEM (VAMHCS) OBJECTIVES HIV in the VA Neurocognitive profile
More informationORIGINAL CONTRIBUTION. Factors Associated With Incident Human Immunodeficiency Virus Dementia
ORIGINAL CONTRIBUTION Factors Associated With Incident Human Immunodeficiency Virus Dementia Yaakov Stern, PhD; Michael P. McDermott, PhD; Steven Albert, PhD; Donna Palumbo, PhD; Ola A. Selnes, PhD; Justin
More informationDOI: /hiv British HIV Association HIV Medicine (2013), 14, SHORT COMMUNICATION
DOI: 10.1111/hiv.12008 SHORT COMMUNICATION Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless
More informationAntiviral Therapy 2013; 18: (doi: /IMP2560)
Antiviral Therapy 2013; 18:153 160 (doi: 10.3851/IMP2560) Original article Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationnatural history of the disease, there is no rationale for limiting screening of cognitive
Assessment, Diagnosis and Treatment of Human Immunodeficiency Virus (HIV)- associated Neurocognitive Disorders (HAND): AConsensus Report of the Mind Exchange Program Supplementary Materials Full practical
More informationA Study of relationship between frailty and physical performance in elderly women
Original Article Journal of Exercise Rehabilitation 2015;11(4):215-219 A Study of relationship between frailty and physical performance in elderly women Bog Ja Jeoung 1, *, Yang Chool Lee 2 1 Department
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationRates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection Teresa H. Evering a, Allison Applebaum b, Melissa La Mar a,
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationMultisystem Impairment in Perinatally HIV-infected (PHIV) South African Adolescents
Multisystem Impairment in Perinatally HIV-infected (PHIV) South African Adolescents Lisa Frigati, Karryn Brown, Sana Mahtab, Leah Githinji, Diane Gray, Liesel Zuhlke, ሷ Jaqueline Hoare, Mark Cotton, Landon
More informationLearning objectives 6/20/2018
Cognitive impairment of patients with chronic migraine, in a neuropsychological assessment, does not depend on the use of topiramate or comorbidities Ferreira KS, MD, PhD Professor, Neurology Clinic, Medicine
More informationThe association between asymptomatic and mild neurocognitive impairment and adherence to. immunodeficiency virus
Southern African Journal of HIV Medicine ISSN: (Online) 2078-6751, (Print) 1608-9693 Page 1 of 10 The association between asymptomatic and mild neurocognitive impairment and adherence to antiretroviral
More informationHIV-Associated Neurocognitive Disorders An Issue of Growing Importance
Review Article 527 HIV-Associated Neurocognitive Disorders An Issue of Growing Importance Lai Gwen Chan, 1 MBBS, MRCP (UK), MRCPsych (UK), Chen Seong Wong, 2 MBBS, MRCP(UK) Abstract Introduction: HIV-associated
More informationCerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection
ORIGINAL ARTICLE INFECTIOUS DISEASES Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection A. Thiyagarajan 1, L. J. Garvey 1,2, H. Pflugrad 1, P.
More informationWhile great progress has been made in understanding
Human immunodeficiency virus (HIV) DNA in peripheral blood mononuclear cells was previously associated with neuropsychological function. By including individuals encompassing the full range of HIV-1-associated
More informationThe Impact of HIV-Associated Neuropsychological Impairment on Everyday Functioning
Fordham University DigitalResearch@Fordham Psychology Faculty Publications Psychology 2004 The Impact of HIV-Associated Neuropsychological Impairment on Everyday Functioning Robert K. Heaton University
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationDETECTING HIV ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) USING NEUROCOGNITIVE ASSESSMENT TESTS IN UGANDA
DETECTING HIV ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) USING NEUROCOGNITIVE ASSESSMENT TESTS IN UGANDA By LeeAnne Masilela School of Public Health Supervisor: Professor Jonathan Levin School of Public
More informationProcess of a neuropsychological assessment
Test selection Process of a neuropsychological assessment Gather information Review of information provided by referrer and if possible review of medical records Interview with client and his/her relative
More informationHIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital
HIV and Brain Func.on Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital HIV and the Brain When can HIV affect the brain? Seroconversion Long term infected (not
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationAPPENDIX A. Search Strategy. Medline
Appendix_Zipursky APPENDIX A Search Strategy Medline Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) Search Strategy: --------------------------------------------------------------------------------
More informationReduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationSupplementary Online Content
Supplementary Online Content Sun LS, Li G, Miller TLK, et al. Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. JAMA. doi:10.1001/jama.2016.6967
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More informationDate of study period: April 12 May 7, 2010 and August September, 2010
Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010
More informationScreening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia Screening Questionnaire
ORIGINAL ARTICLE https://doi.org/10.30773/pi.2017.08.24 Print ISSN 1738-3684 / On-line ISSN 1976-36 OPEN ACCESS Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection Jeffrey J. Sevigny, MD; Steven M. Albert, PhD; Michael
More informationEmerging Considerations in neuroaids Internationally: Events in Acute and Early Infection
Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection Igor Grant, M.D. Director, HIV Neurobehavioral Research Center University of California, San Diego Although combination
More informationLambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
More information